Biomeme
Comparative Evidence

GLP-1 Drug Evidence Scorecard.

How do major GLP-1 medications compare on published clinical trial evidence and molecular pathway characterization? We evaluate each drug across five objective dimensions.

Evidence Evaluation Methodology

Each drug is evaluated across 5 dimensions (20 points each, 100 total) using published clinical trial data and transcriptomic pathway characterization. This scorecard reflects published clinical literature, not individual patient response predictions.

20

mRNA Monitoring

20

Weight Loss Efficacy

20

Tolerability

20

CV Evidence

20

Muscle Preservation

Published Grade Scale

A+ 95–100
A 88–94
A− 82–87
B+ 76–81
B 68–75
B− 62–67
C+ 54–61
C 44–53
C− 38–43
D 30–37
F < 30
#1
83 B+

Mounjaro

Tirzepatide

Dual GIP/GLP-1 agonist with the highest weight loss efficacy in trials.
#2
83 B+

Wegovy

Semaglutide 2.4 mg

The weight management formulation with the strongest cardiovascular evidence.
#3
82 B+

Ozempic

Semaglutide 0.5–2.0 mg

The most recognized GLP-1 brand — proven glycemic and weight management.
#4
81 B+

Zepbound

Tirzepatide

Tirzepatide branded for weight management — same molecule as Mounjaro.
#5
76 B

Rybelsus

Oral Semaglutide 3/7/14 mg

The first and only oral GLP-1 peptide — pill convenience with biological hurdles.
#6
71 B-

Victoza

Liraglutide 1.8 mg

The proven daily GLP-1 for diabetes with established cardiovascular benefit.
#7
68 C+

Saxenda

Liraglutide 3.0 mg

First-generation daily GLP-1 for weight management — superseded by weekly options.

Frequently Asked Questions

What is a GLP-1 receptor agonist?
GLP-1 receptor agonists are a class of medications that mimic the incretin hormone GLP-1, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. They are FDA-approved for type 2 diabetes and/or chronic weight management.
How is the GLP-1 Clinical Evidence Score calculated?
Each drug is evaluated across five dimensions (20 points each, 100 total): transcriptomic pathway characterization, weight loss efficacy (published trial data), tolerability (trial completion rates), cardiovascular outcome evidence, and lean mass preservation data. Scores reflect published clinical literature and trial findings, not individual patient response predictions.
What does the mRNA Monitoring Compatibility score mean?
This dimension reflects how thoroughly a drug's downstream metabolic and inflammatory pathways have been characterized in published transcriptomic literature. Medications with well-mapped gene pathways allow researchers and clinicians to more readily interpret downstream cellular dynamics.
Should I choose my GLP-1 medication based on this scorecard?
No. This comparative scorecard is strictly for educational and informational purposes and does not constitute medical advice. Medication selection must be made with a licensed prescribing provider based on individual medical history, clinical indications, insurance coverage, and treatment goals.
Founding Cohort

Track Your GLP-1 Response — Cohort Now Forming

Real mRNA data on whether your therapy is working. Reserve your spot today to lock in founding pricing before the general public.